Dehydrodiisoeugenol

Synonyms: 脱氢二异丁香酚
Dehydrodiisoeugenol 是一种具有口服活性的抗炎剂和抗肿瘤剂,可抑制结直肠癌细胞增殖并诱导细胞凋亡 (apoptosis)、自噬 (autophagy)、内质网应激和细胞周期阻滞,也可通过抑制 NF-κB 的激活及 COX-2 表达发挥抗炎作用,可用于结直肠癌、炎症性疾病及溃疡性结肠炎的相关研究。
产品编号: MS-Z39875 纯度: 99.98% CAS No.: 2680-81-1 分子式: C20H22O4 分子量: 326.39
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
1mg
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
20mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价

产品描述

Dehydrodiisoeugenol 是一种具有口服活性的抗炎剂和抗肿瘤剂,可抑制结直肠癌细胞增殖并诱导细胞凋亡 (apoptosis)、自噬 (autophagy)、内质网应激和细胞周期阻滞,也可通过抑制 NF-κB 的激活及 COX-2 表达发挥抗炎作用,可用于结直肠癌、炎症性疾病及溃疡性结肠炎的相关研究。

生物实验数据

生物活性 Dehydrodiisoeugenol is an orally active anti-inflammatory and antitumor agent that inhibits colorectal cancer cell proliferation and induces apoptosis, autophagy, endoplasmic reticulum stress, and cell cycle arrest, and also exerts anti-inflammatory effects by inhibiting NF-κB activation and COX-2 expression, making it useful for research on colorectal cancer, inflammatory diseases, and ulcerative colitis.
IC50 & Target

NF-κB; COX-2

体外研究
(In Vitro)

Dehydrodiisoeugenol (0.001-1000 μM;24-72 h) 可呈时间和剂量依赖性抑制人结直肠癌 HCT 116 细胞和 SW620 细胞的活力,其作用 48 h 的 IC50 值分别为 54.32 μM 和 46.74 μM,且对人正常结肠上皮 NCM460 细胞的活性抑制作用较弱。
Dehydrodiisoeugenol (20-60 μM; 48 h) 可降低人结直肠癌 HCT 116 和 SW620 细胞的自我更新能力与集落形成能力,并诱导细胞周期阻滞、自噬和内质网应激。
Dehydrodiisoeugenol (0.1-10 μM; 3.5-6.5 h) 可强效抑制 RAW264.7 小鼠巨噬细胞中 LPS (MS-X54539) 诱导的 COX-2 表达,且不影响组成型 COX-1 的表达。
Dehydrodiisoeugenol (0.1 μM; 1 h) 可抑制 RAW264.7 小鼠巨噬细胞中 LPS 诱导的、依赖磷酸化的 IκB-α 蛋白水解。
Dehydrodiisoeugenol (0.1 μM; 6.5 h) 可抑制 LPS 刺激的 RAW264.7 小鼠巨噬细胞中 NF-κB 的转录活性。
Dehydrodiisoeugenol (2.5-10 μM; 24 h) 可抑制经 LPS/IFNγ 刺激的 RAW264.7 巨噬细胞中 NO 和 PGE2 的生成,iNOS、COX2 和 NOD2 的表达,MAPK、NF-κB 通路的激活。
Dehydrodiisoeugenol (20-40 μM; 0-10 days) 可抑制 HCT116 结直肠癌细胞的集落形成与增殖,诱导细胞凋亡、自噬和周期阻滞。

Cell Viability Assay

Cell Line: human colorectal cancer cell lines HCT 116, SW620; normal human colon epithelial cell NCM460
Concentration: 0.001, 0.01, 0.1, 1, 10, 20, 40, 60, 80, 100, 125, and 1000 μM
Incubation Time: 24 h, 48 h, 72 h
Result: Inhibited cell viability in a time- and dose-dependent manner in HCT 116 and SW620 cells.
Showed significantly higher IC50 for normal NCM460 cells than colorectal cancer cell lines.

Western Blot Analysis

Cell Line: human colorectal cancer cell lines HCT 116, SW620
Concentration: 20, 40 and 60 μM
Incubation Time: 0 h, 12 h, 24 h, 48 h
Result: Significantly increased the expression of p21 protein in a dose- and time-dependent manner.
Significantly reduced the expression of CDK2, CDK4, Cyclin D1, Cyclin E1, and Cyclin E2 proteins in a dose- and time-dependent manner.

Western Blot Analysis

Cell Line: human colorectal cancer cell lines HCT 116, SW620
Concentration: 20, 40 amd 60 μM
Incubation Time: 48 h
Result: Upregulated the expression of LC3B-II, ATG7, and p62 proteins in a dose-dependent manner.\n
Upregulated the expression of BiP, Ero1-Lα, PERK, p-eIF2α, IRE1α, XBP-1s, and CHOP proteins in a dose-dependent manner.

Western Blot Analysis

Cell Line: human colorectal cancer cell lines HCT 116, SW620
Concentration: 60 μM (48 h; 6 h for EBSS co-treatment)
Incubation Time: 6 h, 48 h
Result: Reduced LC3B-II levels when co-treated with 3-MA compared to DEH alone. Did not cause a further increase in LC3B-II levels when co-treated with CQ or Baf A1 compared to DEH alone.

Western Blot Analysis

Cell Line: RAW264.7 murine macrophages
Concentration: 0.1 μM
Incubation Time: 30 min pre-incubation, followed by 30 min LPS stimulation
Result: Significantly inhibited LPS-stimulated phosphorylation of IκB-α.
Prevented LPS-induced degradation of total IκB-α protein.

Western Blot Analysis

Cell Line: LPS/IFNγ-stimulated RAW264.7 macrophages
Concentration: 2.5, 5 and 10 μM
Incubation Time: 24 h
Result: Significantly inhibited the expression of iNOS and COX2, with the most pronounced effect at 10 μM.
Inhibited the phosphorylation of IKKα/β and IκBα at 5 and 10 μM.
Inhibited IκBα degradation and NF-κB p65 nuclear translocation at 10 μM.
Significantly inhibited the phosphorylation of ERK, JNK, and p38 at 2.5, 5, and 10 μM.
体内研究
(In Vivo)

Dehydrodiisoeugenol (40 mg/kg; i.p.; once every other day; 2 weeks) 可显著抑制小鼠 CDX 和 PDX 模型中的结直肠癌肿瘤生长,降低肿瘤细胞增殖水平,诱导 ER 应激并改变自噬信号通路,且在小鼠体内表现出低毒性。
Dehydrodiisoeugenol (5-20 mg/kg; i.g.; daily; 8 days) 可通过减轻肠道炎症、恢复屏障功能并抑制 NOD2 表达,剂量依赖性地改善 BALB/c 小鼠中 DSS (MS-A45736) 诱导的溃疡性结肠炎。

Animal Model: NOD/SCID (5-week-old female)
Dosage: 40 mg/kg
Administration: i.p.; once every other day; 2 weeks
Result: Significantly reduced tumor volume in HCT 116, SW620, and PDX xenograft models relative to controls.
Significantly reduced the percentage of Ki67-positive cells (cell proliferation marker) in tumor tissues relative to controls.
Significantly upregulated expression of ER stress-related proteins (BiP, PERK, IRE1α) and autophagy-related proteins (LC3B-II, p62) in harvested tumors relative to controls.
Showed no significant changes in mouse body weight, and H&E staining of heart, liver, spleen, lung, and kidney tissue revealed no pathological abnormalities indicative of toxicity.
Animal Model: BALB/c (male, 6-8 weeks old, 20-22 g, ulcerative colitis model via 3.5% DSS gavage)
Dosage: 5 mg/kg; 10 mg/kg; 20 mg/kg
Administration: p.o.; daily; 8 days
Result: Significantly increased mouse body weight and colon length compared to the DSS model group.\n
Dose-dependently reduced colon mucosal damage, edema, and inflammatory cell infiltration, with partial recovery of goblet cells and crypts.
Significantly restored colonic ZO-1 and Occludin protein expression at 20 mg/kg to improve intestinal barrier function.\n
Dose-dependently significantly reduced colon MPO levels and serum TNF-α, IL-6, and IL-1β levels.
Significantly reduced colonic NOD2 protein expression at 10 mg/kg and 20 mg/kg.
性状 固体
颜色 White to off-white

化学信息

分子量 326.39
分子式 C20H22O4
CAS No. 2680-81-1
别名 脱氢二异丁香酚

储存&溶解度

体内实验配方
10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (6.13 mM), Sonication is recommended.
请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。
储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (306.38 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM3.0638 mL15.3191 mL30.6382 mL76.5955 mL
5 mM0.6128 mL3.0638 mL6.1276 mL15.3191 mL
10 mM0.3064 mL1.5319 mL3.0638 mL7.6595 mL
15 mM0.2043 mL1.0213 mL2.0425 mL5.1064 mL
20 mM0.1532 mL0.7660 mL1.5319 mL3.8298 mL
25 mM0.1226 mL0.6128 mL1.2255 mL3.0638 mL
30 mM0.1021 mL0.5106 mL1.0213 mL2.5532 mL
40 mM0.0766 mL0.3830 mL0.7660 mL1.9149 mL
50 mM0.0613 mL0.3064 mL0.6128 mL1.5319 mL
60 mM0.0511 mL0.2553 mL0.5106 mL1.2766 mL
80 mM0.0383 mL0.1915 mL0.3830 mL0.9574 mL
100 mM0.0306 mL0.1532 mL0.3064 mL0.7660 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础